Loading
Organised follow-up for the 18 million US and 50+ million global cancer survivors: watching for recurrence and second cancers, managing long-term side effects such as heart damage, infertility, neuropathy and fatigue, and helping people return to work and life.
The IOM report 'From Cancer Patient to Cancer Survivor: Lost in Transition' (2006) launched survivorship as a phase of care and recommended a written survivorship care plan (SCP). Trials of SCPs alone showed little benefit (Grunfeld 2011), and the ACoS dropped the SCP mandate in 2020 in favour of comprehensive survivorship programmes. Core content: risk-based surveillance (COG Long-Term Follow-Up Guidelines for childhood cancer survivors, who have >95% cumulative chronic-condition incidence by age 50, St Jude Lifetime Cohort), cardio-oncology, endocrine and fertility issues, second primary cancers, neurocognitive effects, fatigue, sexual health, psychosocial and employment support, and health promotion. Delivery models: oncologist-led, nurse-led, shared care with primary care, and risk-stratified pathways (NHS personalised stratified follow-up). Adolescent and young adult survivors and rural/minority survivors have the largest gaps.
Risk-stratified, guideline-based lifelong surveillance and management of late effects, with explicit transfer of information and responsibility between oncology and primary care, and attention to the whole person (work, finances, relationships).
An old antidote proven in two paediatric trials to halve permanent hearing loss from cisplatin, and approved in 2022 as the first drug to prevent a chemotherapy side effect in children.
Query for this technology: (TITLE:"Survivorship care and late-effects surveillance" OR ABSTRACT:"Survivorship care and late-effects surveillance") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Survivorship care and late-effects surveillance, not a curated reading list.
Shares Frailty and late effects in survivors, Nodal marginal zone lymphoma, Splenic marginal zone lymphoma, What actually works after treatment and the tag supportive.
Shares After treatment in the Nordic countries: rehabilitation written into the pathway, The carer's own recovery: what is known about the person who is not the patient, Nodal marginal zone lymphoma, Splenic marginal zone lymphoma and the tag supportive.
Shares Bowel function after pelvic radiotherapy, Cancer rehabilitation: the discipline that puts function back, Geriatric assessment, Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards and the tag supportive.
Shares Bone-modifying agents (bisphosphonates, denosumab), Relapsed and refractory classical Hodgkin lymphoma, Mantle cell lymphoma, Small-cell lung cancer and the tag supportive.
Shares Bone-modifying agents (bisphosphonates, denosumab), Bone loss caused by cancer treatment, and what rebuilds it, Lung cancer (all types), Triple-negative breast cancer (TNBC) and the tag supportive.
Shares Bone-modifying agents (bisphosphonates, denosumab), Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards, Small-cell lung cancer, Lung cancer (all types) and the tag supportive.
Shares Prospective surveillance: looking for the problem before it becomes a disability, What has actually been implemented since those trials, and what has not, How recovery is measured: the questionnaires behind the numbers, Psycho-oncology and distress screening and the tag supportive.
Shares Cardio-oncology, Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards, Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Acute lymphoblastic leukaemia and the tag supportive.